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Introduction: There is an increasing awareness to counteract problems due to incorrect
antimicrobial use. Interventions that are implemented are often part of an Antimicrobial
Stewardship Program (ASPs). Studies publishing results from these interventions are
increasing, including reports on the economical effects of ASPs. This review will look
at the economical sections of these studies and the methods that were used.
Methods: A systematic review was performed of articles found in the PubMed and
EMBASE databases published from 2000 until November 2014. Included studies found
were scored for various aspects and the quality of the papers was assessed following
an appropriate check list (CHEC criteria list).
Results: 1233 studies were found, of which 149 were read completely. Ninety-nine were
included in the final review. Of these studies, 57 only mentioned the costs associated with
the antimicrobial medication. Others also included operational costs (n = 23), costs for
hospital stay (n = 18), and/or other costs (n = 19). Nine studies were further assessed
for their quality. These studies scored between 2 and 14 out of a potential total score
of 19.
Conclusions: This review gives an extensive overview of the current financial evaluation
of ASPs and the quality of these economical studies. We show that there is still major
potential to improve financial evaluations of ASPs. Studies do not use similar nor
consistent methods or outcomemeasures, making it impossible draw sound conclusions
and compare different studies. Finally, we make some recommendations for the future.
Keywords: antibiotic stewardship, antibiotic resistance, health economics and outcomes research, costs and
costs analysis, economic evaluation
Introduction
The therapeutic use of antimicrobials in clinical medicine is continuing to be suboptimal. Both
overtreatment, with regard to spectrum and duration, and suboptimal treatment, with regard to
dosage and most effective therapy, are areas of concern. Either one can lead to an increase in the
resistance of bacteria (Goossens, 2009), and unnecessary side effects, including a potentially large
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economic burden (Gandra et al., 2014). It is thus imperative
that action is taken (Carlet et al., 2011; World Health Orga-
nization, 2012). Fortunately, many hospitals are aware of this,
and act accordingly by implementing Antimicrobial Stewardship
Programs (ASPs) in their institutions. These programs differ in
approach, but the consensus is that when implemented correctly,
considerable positive (clinical) effects can be attained by optimiz-
ing patients’ antimicrobial therapy (Davey et al., 2013). Notably,
problems such as increased antimicrobial resistance, consequent
treatment failure, and the spread of nosocomial infections can
be prevented with ASPs, inclusive its financial consequences
(Roberts et al., 2009). Implementing an ASP can thus also have
a considerable positive financial impact within a hospital, which
is crucial in times where healthcare costs are rising.
There are various guidelines published describing to design
an ASP (Dellit et al., 2007; SWAB, 2012; With de et al., 2013),
consisting of a set of interventions and services, all with the goal
to stimulate the correct use of antimicrobials, but intervening at
different moments in the chain of care. One or more ASPs can
be implemented, depending on the type of hospital, the types of
patients and the local challenges that physicians face. In general,
all tasks within an ASP can be categorized within three blocks:
• The first block consists of tasks that can be performed dur-
ing the start of empirical antimicrobial therapy (the so-called
“front-end” approach). Examples are pre-analytic consulta-
tions and providing therapy guidelines and education for
prescribing doctors.
• A second block consists of tasks to assist by the optimization
of the therapy around day 2–3, such as interventions to pro-
mote IV to oral switch, de-escalation and a timely stop when
appropriate (the “back-end” approach).
• Finally, a last block of supplemental tasks should assure eval-
uation of hospital data and tasks that act upon those data
accordingly, like updating guidelines using local resistance
rates and processes, as well as promoting surveillance studies
(Dellit et al., 2007; SWAB, 2012; With de et al., 2013).
Whether the intervention is restrictive or persuasive does not
seem to differ on the long-term—i.e., after 6 months of imple-
mentation (Davey et al., 2013).
During the last years, there is a steady rise in papers published
on above mentioned interventions. Coinciding with that rise, the
number of economic evaluations of an ASP is also increasing.
This reflects the growing importance of health economic evalu-
ations in general, which is seen across the world, as well as that
of ASPs in particular (Hjelmgren et al., 2001). However, there
seems to be a large variation in the way ASPs are financially
evaluated. Often only the direct costs for antimicrobials is taken
into account, whereas other (in)direct costs may have a much
larger impact (McGowan, 2012; Davey et al., 2013). Many papers
mention some costs and/or benefits, but only a few give usable,
in-depth data, analyses and conclusions. When comparing finan-
cial ASP results, for example, within the latest Cochrane review,
the conclusion was that economic evaluations are done in a “dis-
appointingly” low number of studies and often lack reliable data
(Davey et al., 2013).
This study provides a systematic methodological review of
published economic evaluations of ASP studies (intervention
studies with an economic evaluation paragraph or complete eco-
nomic evaluations). Ideally, it will shed light on the divergence
that is present in these studies and where improvement is neces-
sary. Keeping in mind that decision makers use these economic
evaluations in their daily practice nowadays, and costs are consid-
ered a barrier to implement an ASP, correct and valuable studies
are becoming more important (Johannsson et al., 2011). This
review will therefore in particular look at the methods’ usability
for others that might want to implement an ASP in their hospital.
Materials and Methods
A search was performed within the PubMed and EMBASE
databases in November 2014, using the following search
strings: “antimicrobial stewardship,” “antimicrobial manage-
ment,” “antimicrobial prescribing intervention,” and “antimicro-
bial program intervention.” All strings were in combination with
the words “cost(s),” “financial,” “economic,” “dollar” or “euro,” or
the respective symbols for the latter two. All abstracts found were
read and original studies written in English, Dutch or German
that discussed an intervention the related economic analysis of
that intervention within a hospital were included. Considering
the fast developments within the field of antimicrobial steward-
ship as well as within health economics, studies before 2000 were
excluded. Outpatient settings were excluded (see Figure 1 for the
complete flow chart).
The final set of included papers was read completely, and for
each study the type of economic evaluation done was scored.
Keeping in mind that many studies are clinical effect studies and
not economic analyses studies, the papers that only mentioned
direct antimicrobial costs without mentioning any of the other
relevant costs or savings, were categorized as an Antimicrobial
Cost Analysis (ACA). The remainder of the studies contained
enough essential financial parameters to be classified as differ-
ent economic analyses (e.g., as described in Drummond et al.,
2005). For studies looking at the effects of two methods and
that converted those effects into monetary values the classifica-
tion Cost-Benefit Analyses (CBA) was used. Those that evalu-
ated the relative costs and effects of two different methods were
classified as Cost-Effectiveness Analyses (CEA). Studies observ-
ing the different costs and effects of two methods were classi-
fied as Cost-Consequence Analyses (CCA). Studies that looked
at the costs but not at the effects were scored as Cost-Analyses
(CA) and studies that looked at the differences in costs assuming
similar effects between the two evaluated methods were scored
Cost-Minimization Analyses (CMA). For the papers the follow-
ing parameters were scored: year, journal, country of research,
study design, setting, number of participants, outcome mea-
sures, price adjustment, and/or discounting measures, and con-
clusions. The types of intervention per study were scored and
categorized.
Within an economic analysis, different costs can be taken into
consideration. Drummond et al. recommend calculating opera-
tional costs and capital costs that are related to the intervention
(Drummond et al., 2005). To further specify this for an ASP
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FIGURE 1 | Flow chart of the search method. The followed search method
as performed on 4 November 2014.
intervention study, the outcome measures from the Cochrane
review were taken as specific parameters (Davey et al., 2013).
Depending on the perspective chosen, the following parameters
were scored: implementation costs, operational costs (person-
nel and/or equipment costs of the intervention), antimicrobial
costs, hospital day costs, morbidity, and/or mortality costs (costs
associated with hospital procedures, treatment etc.), societal costs
(costs occurring outside the hospital from a societal perspective,
e.g., loss of productivity), and other costs (costs mentioned by a
study that are different than already mentioned here).
In order to assess the level of quality of the included papers,
an appropriate quality criteria list (Consensus on Health Eco-
nomics Criteria [CHEC] list) was used (Evers et al., 2005). A
criteria list specifically intended to give insight in the quality of
economic evaluations. Considering the fact that many studies
lacked a proper economic analysis it was not deemed of great
interest or informative doing an in depth quality assessment on
all papers of which the majority would not meet minimum cri-
teria. We therefore decided to only formally assess the quality in
detail if the papermetminimum standards. Two parameters were
assumed as most basic and essential for an economic evaluation
studies and used as an inclusion criterion: implementation costs
and/or operational costs and appropriate valuation of all costs.
Articles that included these parameters were consequently scored
following the CHEC list by two authors independently.
This review study followed the PRISMA criteria where possi-
ble (Moher et al., 2009). The complete checklist can be found as
Supplementary Material (Supplemental Table 1).
Results
For this review, a total of 1233 papers were found using our
search strings. Of these papers, 1083 were excluded based upon
the fact that they did not meet our inclusion criteria (for exam-
ple, because they were review papers, there were no cost outcome
measures mentioned or they were published in a non-included
language). One hundred and forty-nine papers were included
and read completely. Of these papers, a further 50 were excluded
for various reasons. A set of 99 papers was included in the final
analysis (Figure 1).
Baseline Characteristics
From the total of 99 papers, the majority came from the United
States followed by Europe and most included studies were pub-
lished within the last 3 years. Studies were performed in hospi-
tals ranging from as little as 39 beds to as much as 1800 beds
and included between 50 and 40,000 patients. For a complete
overview see Table 1.
Types of Interventions
Categorizing the stewardship interventions in block 1 (front-end
approach), block 2 (back-end approach), and block 3 (supple-
mental measures), most studies implemented one or more inter-
ventions from block 2 (Table 2). Particularly, the implementation
of an audit of and/or feedback on the therapy provided at cer-
tain time-point(s) was performed frequently (62 studies; 52% of
all interventions). Second most frequent was the creation and
implementation of antimicrobial therapy guidelines (16 studies,
13% of all interventions). 18 studies (18% of all studies) imple-
mented more than one intervention at the same time, providing
a “bundle” of services.
Types of Analyses
Fifty-seven (58%) papers only included antimicrobial costs as an
economic outcome measure without any of the other relevant
costs. Although these studies looked at costs and effects, they
could not be classified as a proper economic analysis, because
an appropriate economic evaluation was not done. They were
therefore classified as an ACA. Of the rest, the majority, 32 were
scored as a CBA. Three studies evaluated the relative costs and
effects classifying them as a CEA. There were 3 CCAs, 2 studies
only looked at the costs making it a CA and 2 studies were CMAs
(Table 3).
Cost Outcome Measures
For every study, the cost outcome measures they used were
scored. None of the papers included all. Every study took a hos-
pital perspective when looking at the costs and benefits, although
only a few explicitly mention this. None of the studies performed
their analysis from a societal perspective, although comments
weremade on the importance of including these costs. Disregard-
ing the societal costs, there were 3 (3%) studies that included all
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TABLE 1 | General characteristics of the reviewed studies (n = 99).
Characteristic Number Percentage
GEOGRAPHY
North America 51 52%
South America 3 3%
Europe 28 28%
Asia 14 14%
Africa 2 2%
Australia 1 1%
PUBLICATION YEAR
2000–2003 8 8%
2003–2006 14 14%
2006–2009 17 17%
2009–2012 13 13%
2012–2014 47 47%
STUDY DESIGN
ITS 8 8%
Quasi-experimental study 65 66%
Retrospective evaluation 12 12%
(R)CT 8 8%
Cost-analysis 2 2%
Observational study 3 3%
Unclear 1 1%
NUMBER OF BEDS IN HOSPITAL
<150 10 10%
150–500 24 24%
500–1000 27 27%
>1000 12 12%
Unclear 23 23%
NUMBER OF PATIENTS INCLUDED
<100 10 10%
100–250 22 22%
250–500 14 14%
500–1000 6 6%
1000–1500 6 6%
>1500 10 10%
Unclear 31 31%
of the other parameters (Frighetto et al., 2000; Gross et al., 2001;
Hamblin et al., 2012), 3 (4%) more studies included all but imple-
mentation costs (and, as stated, societal costs) (Bauer et al., 2010;
Niwa et al., 2012; Perez et al., 2013). Fifty-seven studies (58%)
only included antimicrobial costs (Table 4).
Quality Assessment
Following the criterion as stated in the Material and Methods
section, 9 studies included operational costs of the intervention
and appropriately valued their costs by taking into account infla-
tion and/or price changes (Al Eidan et al., 2000; Frighetto et al.,
2000; Gross et al., 2001; Ansari et al., 2003; Rüttimann et al., 2004;
Oosterheert et al., 2005; Hamblin et al., 2012; Sick et al., 2013).
For these studies, quality was assessed following the CHEC list
and results are mentioned in Table 5. Results ranged between 2
TABLE 2 | Types of interventions of the reviewed papers.
Block Interventions Number Percentage Patients
1 Altered therapy
guidelines
16 16% 32,103
Antibiotic restriction lists
or pre-authorization
12 12% 70,446
Giving education 10 10% 21,913
Antibiotic cycling 1 1% –
Pre-analytic
consultations
1 1% 100
New therapy 1 1% 2888
2 Therapy evaluation,
review and/or feedback
62 63% 51,506
Rapid diagnostic tools 9 9% 701
New biomarkers 2 2% –
3 Producing local use and
resistance data
5 5% 19,390
Performed interventions per category, the number of studies that evaluated this interven-
tion, the percentage of the total and the total number of patients (if this was mentioned in
the papers).
TABLE 3 | Types of economic evaluation of the reviewed papers.
Type of analysis Number Percentage
CA 2 2%
CMA 2 2%
CBA 32 32%
CCA 3 3%
CEA 3 3%
CUA 0 0%
ACA 57 57%
CA, Cost-Analysis; CMA, Cost-Minimization Analysis; CBA, Cost-Benefit Analysis; CCA,
Cost-Consequence Analysis; CEA, Cost-Effectiveness Analysis; CUA, Cost-Utility Analy-
sis; ACA, Antimicrobial Cost Analysis.
and 14 positives on the criteria of a maximum of 19, with 3 stud-
ies scoring less than 10. An incremental analysis of the costs and
health outcomes, and sensitivity analyses were among the items
most frequently missed.
Discussion
Concluding it can be said that economic evaluations of ASPs have
room for improvement. Often the methods chosen are insuffi-
cient to be conclusive, because essential parameters are missing
and multiple different approaches to evaluate an ASP are being
used. It is therefore in most cases difficult if not impossible to
translate results to other settings. Even relatively simple parame-
ters, such as number of patients, study design and setting, per-
spective chosen, performed statistics, and inflation corrections
are frequently missing. Often the evaluation was done on a set of
interventions, making their respective benefits undistinguishable.
The lack of quality is further reflected in the fact that only 9 stud-
ies could be included in the quality assessment and none scored
above 14 (of a maximum of 19), underlining the need for a more
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systematic approach for these types of studies. A meta-analysis
of published results, which had the preference, could therefore
not be performed. Thus, the focus of this review was switched to
highlighting the possible areas for improvement.
The primary goal for an ASP should be to improve patient
outcomes and quality of care. It is shown that running an effec-
tive ASP can optimize antimicrobial therapies thereby improving
patients’ treatment (Davey et al., 2013). This can in turn positively
affect local resistance rates and local nosocomial infections rates.
Some studies also showed the positive effect an ASP could have
TABLE 4 | Scored outcome parameters of the reviewed papers.
Outcome measures Number Percentage
Implementation costs 11 11%
Antimicrobial costs 97 98%
Operational costs 23 23%
LOS costs 18 18%
Morbidity/mortality costs 14 14%
Other hospital costs 19 19%
Societal costs 0 0%
LOS, length of stay.
on the length of stay (LOS) of a patient (e.g., Al Eidan et al.,
2000; Frighetto et al., 2000; Niwa et al., 2012; Yen et al., 2012;
Perez et al., 2013; Rimawi et al., 2013; Sick et al., 2013). Such a
reduction can improve patient safety and quality of care as well.
Keeping this in mind, it is worthwhile to also look at the effec-
tiveness of stewardship programs, especially from an economical
point of view. Obviously, it is highly preferably if this is per-
formed according to a set of guidelines (Drummond et al., 2005).
We have shown that major room for improvement in this area
still exists.
Ideally, an economic evaluation begins with defining the type
of intervention that is performed and the perspective that is
chosen to do the evaluation. Most papers reviewed seemingly
chose a hospital perspective, although few mention this explic-
itly. A societal perspectivemight be preferred inmany cases, since
patients and society in general will benefit from the interven-
tion, especially when a reduction in the antimicrobial resistance
rates is achieved, or when LOS is reduced. By merely looking at it
from a hospital perspective, such benefits are lost or marginalized
(Chen, 2004). Effects of interventions are dependent on the local
epidemiological data on resistance, and consequently this will
influence the total benefits and should thus not be overlooked.
If the economic evaluation is done from a hospital perspec-
tive, the costs of the program will consequently be the ones made
TABLE 5 | Results of CHEC list score.
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Is the study population clearly described? Yes No No Yes No Yes Yes Yes No
Are competing alternatives clearly described? No No No Yes No Yes No Yes Yes
Is a well-defined research question posed in answerable form? Yes No No No Yes Yes Yes Yes Yes
Is the economic study design appropriate to the stated objective? Yes No Yes Yes Yes Yes Yes Yes Yes
Is the chosen time horizon appropriate to include relevant costs and
consequences?
Yes No No No Yes No Yes Yes Yes
Is the actual perspective chosen appropriate? Yes Yes Yes Yes Yes Yes Yes Yes Yes
Are all important and relevant costs for each alternative identified? No No Yes Yes No Yes Yes No Yes
Are all costs measured appropriately in physical units? Yes No Yes No Yes No Yes Yes No
Are costs valued appropriately? Yes No Yes No No No Yes Yes Yes
Are all important and relevant outcomes for each alternative identified? Yes No Yes Yes No Yes No Yes Yes
Are all outcomes measured appropriately? Yes No Yes Yes No No No Yes Yes
Are outcomes valued appropriately? Yes No Yes Yes No Yes No Yes Yes
Is an incremental analysis of costs and outcomes of alternatives performed? No No No No No No No No Yes
Are all future costs and outcomes discounted appropriately? Yes No Yes Yes Yes Yes Yes Yes Yes
Are all important variables, whose values are uncertain, appropriately
subjected to sensitivity analysis?
No No No No No No No No Yes
Do the conclusions follow from the data reported? No No Yes Yes Yes No No Yes Yes
Does the study discuss the generalizability of the results to other settings
and patient/client groups?
Yes No Yes No No No No No No
Does the article indicate that there is no potential conflict of interest of study
researcher(s) and funder(s)?
Yes Yes No Yes Yes No Yes No No
Are ethical and distributional issues discussed appropriately? No No No No No No No No No
Total score 13 2 11 11 8 9 10 13 14
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by the hospital. These can be categorized as fixed and variable.
Fixed costs are those that do not vary with the quantity of output
(i.e., number of patients) in the short run and include for example
rent, equipment, maintenance etc. (Drummond et al., 2005). For
hospitals, studies showed that fixed costs can range from 65% up
to 84% of the total budget. The latter percentage also included the
personnel costs in their calculations (Roberts et al., 1999; Taheri
et al., 2000). Staff salaries can be considered fixed or semi-fixed,
especially on the short-term. This means that for an ASP, which is
often evaluated on the short-term, direct cost reductions in prac-
tice can primarily be expected in the variable costs. There is a
need for a longer term perspective in economic evaluations of
ASPs.
Almost all interventions require time, resources, and some-
times equipment to implement. These costs should not be over-
looked. Not all community hospitals have the same resources
available as large academic centers, and implementation costs
can therefore be a major hurdle (Johannsson et al., 2011). Of the
reviewed papers however, only 11 studies (11%) mentioned the
costs spent on implementation.
For amajority of the reviewed studies (58%), the only included
cost outcome parameter was the cost price of antimicrobials.
These costs are obviously easier to obtain and measure than oth-
ers. It is also one of the only ways for an ASP to significantly
influence the variable budget of the hospital. When evaluating
the costs of antimicrobials however, it is still important to adjust
prices to a single year/level in order to remove the bias of chang-
ing prices/inflation. Of the included studies only 14 (14%) did
so. Prices of antimicrobials change over time, due to inflation,
but also because patents can expire and (cheaper) generic sub-
stitutes can become available. This becomes especially important
when a study evaluates several years of antimicrobial acquisition
costs. The longer the study period is, the higher the chance that
more generic substitutes became available due to expired patents.
With more than 5 generic products entering the market, prices of
the original brand antibiotic can drop by more than 75% (FDA,
2010). Furthermore, prices yearly chance in reality due to chang-
ing agreements between hospitals and external parties. It is there-
fore essential that during a financial evaluation of an ASP the
prices are fixed for the whole study.
Performing the interventions, costs time and time spent
invokes opportunity costs. This implies that the time doctors or
pharmacists spend on the ASP cannot be spent on something else.
This time should thus also be included in an economic evalua-
tion. There are multiple ways to measure the time that was put
into the program and each method has his pros and cons, as indi-
cated by Page et al. (2013) in an overview of various methods
(Page et al., 2013). When looking at the total costs of the time
spent, it is important to include all personnel costs (salary and all
related attributable on-costs) to give the most realistic monetary
output.
One of the results of an ASP can be the reduction of LOS.
From a financial point of view such a reduction is highly inter-
esting because of the high costs that are associated with it. Costs
for a hospital day are however almost completely fixed and will
therefore not change over time due to fewer patient hospital days,
unless wards or beds are closed, but even then depreciation costs
are made (Rauh et al., 2010). This is something to take into con-
sideration. An important question is thus how to value a possible
reduction of the LOS. For hospital days there is no market to
establish a price (Scott et al., 2001). This makes it difficult to aptly
include the effect on LOS in an economic evaluation. Often, stud-
ies look at the costs (fixed and variable) made at a department or
hospital and divide this by the patient days. An indication for
these costs can be calculated by accounting all costs; by look-
ing at the incremental costs for the last (cheaper) day(s) (Taheri
et al., 2000); or by willingness to pay (Stewardson et al., 2014).
The latter study gave a fascinatingly low figure compared to the
other methods, showing that high prices for a hospital day are not
always realistic depending on the perspective. Of the reviewed
papers that mentioned their cost for a hospital day, the average
in 2013 Euro level, was e649.04 per hospital day (Al Eidan et al.,
2000; Barenfanger et al., 2000; Frighetto et al., 2000; Oosterheert
et al., 2005; Forrest et al., 2006; Niwa et al., 2012; Yen et al., 2012;
Maddox et al., 2014). However, because it was not always clear
which costs were included in this figure, it is almost impossi-
ble to draw conclusions based on these numbers. A reduction in
LOS can thus have a difficult to estimate effect on the balance.
Freeing up beds does have however an important positive bene-
fit in the form of an increased possibility to boost the hospital’s
turnover. Reduction of hospital days is thus especially interest-
ing if the backfill of a hospital is large enough to fill up the freed
beds. If this is not the case, fixed costs are divided over less patient
days, and depending on the cost structure, this can even mean
hospital costs rise per patient. Additionally, from a patient per-
spective there are huge benefits in leaving a hospital earlier. These
are covered by taken a broader perspective in the analysis.
A subsequent broader perspective for economical evaluations
is looking at an intervention from a health payer perspective.
This entails the inclusion of costs made by the patient, such as
home medication and costs for a general practitioner. For a soci-
etal perspective, additional indirect and non-medical costs that
occur outside the hospital are included, such as expenses made by
patients like transportation and spent time, but also loss of pro-
ductivity for the society (Drummond et al., 2005). Furthermore,
a patient can live longer or with better quality of life due to an
intervention. One method to take these effects into account is to
measure the quality adjusted live years (QALYs) in a long-term
analytic approach. Together with the costs of the intervention,
a cost-effectiveness ratio can then be calculated. Depending on
the threshold for a QALY gained, an intervention can be judged
financially worthwhile to implement or not. The inherent diffi-
culties of this method (e.g., time and knowledge needed to per-
form this extensive evaluation), especially for a relatively small
intervention program as an ASP, are illustrated by the fact that no
study performed such an analysis. In an outpatient setting how-
ever, Oppong et al. (2013), is a nice example of such a study that
did this analysis.
Results of an economic evaluation of an ASP can be used to
convince a board of directors that pro-actively spending money
on improving antimicrobial therapies can give a positive return
of investment (Johannsson et al., 2011). However, when this is
the main goal of the evaluation, a simple cost (benefit) analysis is
not enough, because it will miss effects outside the hospital. Cost
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effectiveness/utility is more precise, but complex. Preferably, the
department or the hospital thereforemakes a business case model
for an ASP in order to give an, as complete as possible finan-
cial overview. Both Stevenson et al. (2012) and Perencevich et al.
(2007) proposed a similar set-up for this.
To assess the quality of the included papers within this review,
the CHEC list was used (Evers et al., 2005). The Consolidated
Health Economic Evaluation Reporting Standards (CHEERS)
Statement has been used to evaluate the quality of CEAs in
reviews (Husereau et al., 2013). See for example Abu Dabrh et al.
(2014), Hop et al. (2014), and Kawai et al. (2014). However, in
our opinion, the CHEERS checklist is not suitable for this spe-
cific review. It only considers whether something is reported,
not whether the choices were appropriate or justified. As such,
a checked box on the CHEERS checklist is not an assessment of
quality, merely one of completeness. Another recent publication,
the checklist by Caro et al. was specifically designed for a relia-
bility and credibility assessment. However, this checklist is only
applicable for decision models, and as such was not appropriate
for our review (Caro et al., 2012).Therefore, the CHEC list was
chosen, while this, as said, specifically gives insight in the quality
of economic evaluations (Evers et al., 2005).
Concluding, it can be said that there is still much room to
improve economic evaluations of ASPs. Of the papers reviewed,
none can really be used to draw strong economical conclusions.
Using more standardized methods to financially evaluate an ASP
will contribute to the advancement needed in this field and
notably, further research should focus on the harmonization of
this field. Finally, inclusion of the societal perspective, real-world
pricing and a potentially longer time horizon for analysis can be
recommended. Ultimately, these improvements should provide a
more solid basis for decision making, potentially leading to better
patient care.
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